Radiopharmaceuticals have both diagnostic and therapeutic applications and are pivotal to the NHS achieving its aim to diagnose 75% of cancers at stage 1 or 2 by 2028.
Our Radiopharmaceutical Products Framework Agreement ensures that all radiopharmaceutical products and services procured through it comply with the latest regulations; mitigating risks and protecting customers and patients.
It provides radiopharmaceutical products, maintenance, support and training from a carefully selected range of suppliers, which includes radiopharmaceutical kits, diagnostic and therapeutic radiopharmaceuticals, plus a range of generators including technetium and gallium.
Framework Agreement Information
The framework agreement covers a wide range of radiopharmaceutical products including; radiopharmaceutical kits, diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals, technetium generators, krypton generators and 18F-FDG
What dates is the framework agreement active?
12 November 2025 – 11 November 2033
(Reopening for new suppliers at years three and five).
Who can take advantage of the framework agreement?
All NHS organisations across the United Kingdom.
How was the framework agreement procured?
Further competition and direct award
There are two procurement routes for an approved organisation that wishes to use this framework agreement. A competitive process between the suppliers in the relevant Lot, which may be preceded by a capability assessment, or an award without a competitive process to particular supplier(s).
A competitive selection process is the default ordering procedure under this framework agreement.
How we can support?
We offer different levels of support, including SME advice and robust templates for you to easily run your own process, or additional support to design and run a further competition on your behalf.
How can I access the framework agreement?
Access framework agreement documentation via our Customer Framework Agreement Portal (CFAP).
What are the benefits of using this framework agreement?
CONTINUITY OF SUPPLY
Ensures continuity of supply, so NHS organisations can place standing orders for scheduled deliveries with suppliers to ensure uninterrupted product coverage.
ADDRESSES INCREASING DEMAND
Addresses the increasing demand for radiopharmaceuticals, stabilises the cost and ensures a steady and compliant route to market to meet the future needs of the NHS and patients.
COMPLY WITH THE LATEST REGULATIONS
All products and services available comply with the latest regulations, mitigating risks and protecting customers and patients.
FULL COVERAGE OF RADIOPHARMACEUTICALS
Appointed suppliers will be able to bring forward new services throughout the life of the framework agreement to ensure full coverage of radiopharmaceuticals.
IMPROVED PATIENT OUTCOMES
Radiopharmaceutical products play an important role in diagnosing cancer and a range of other conditions by allowing the visualising and targeting of specific areas of the body, supporting earlier intervention and improved patient outcomes.
COST CERTAINTY
The framework agreement can help customers to manage fluctuating price changes by inserting a robust price increase management process. Prices will be held for 12-month periods, but all price changes will be subject to a price increase procedure and four months’ notice.
Supplier Details
Strategic Procurement Support
If this framework agreement doesn’t cover the goods or services you require, or a framework agreement isn’t the optimal route to market for your needs, we can provide tailored strategic procurement support. Find out more here.
Contact the Health Category Team
Try these related framework agreements
The framework agreement has been structured into the following lots: